MX2020010433A - Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.

Info

Publication number
MX2020010433A
MX2020010433A MX2020010433A MX2020010433A MX2020010433A MX 2020010433 A MX2020010433 A MX 2020010433A MX 2020010433 A MX2020010433 A MX 2020010433A MX 2020010433 A MX2020010433 A MX 2020010433A MX 2020010433 A MX2020010433 A MX 2020010433A
Authority
MX
Mexico
Prior art keywords
medicinal
sup
sub
heteroaryl
compound
Prior art date
Application number
MX2020010433A
Other languages
English (en)
Inventor
Tomoyuki Manabe
Tomoya Miura
Shintaro Hirashima
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2020010433A publication Critical patent/MX2020010433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de pirazol sustituidos con heteroarilo o sus sales farmacéuticamente aceptables que tienen una actividad inhibidora de SGLT1 y son útiles para un fármaco, composiciones farmacéuticas que lo comprenden, y su uso farmacéutico; específicamente, un compuesto de fórmula [X]: (ver Fórmula) en donde R1 es hidrógeno o halógeno, R2 es alquilo de C1-6 o haloalquilo de C1-6, el anillo Het es piridilo sustituido o pirazinilo, pirimidinilo o piridazinilo opcionalmente sustituido, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y su uso farmacéutico se proporciona.
MX2020010433A 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. MX2020010433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04
PCT/JP2019/014721 WO2019194207A1 (ja) 2018-04-04 2019-04-03 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MX2020010433A true MX2020010433A (es) 2020-10-28

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010433A MX2020010433A (es) 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.

Country Status (19)

Country Link
US (3) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR20200139696A (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686A (es)
MX (1) MX2020010433A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
KR20220056219A (ko) * 2019-09-04 2022-05-04 니뽄 다바코 산교 가부시키가이샤 병용 의약에 의한 당뇨병의 치료 또는 예방 방법
AU2020343585A1 (en) * 2019-09-04 2022-03-10 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
MX2022011490A (es) 2020-03-19 2022-10-07 Japan Tobacco Inc Tratamiento o metodo de prevencion de falla cardiaca cronica.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE602004028800D1 (en) 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
EP1637539B1 (en) * 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
EP1889842A4 (en) 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
AU2007219509A1 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
AU2007308154A1 (en) * 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途

Also Published As

Publication number Publication date
CN111902408B (zh) 2023-11-14
CN111902408A (zh) 2020-11-06
PE20201068A1 (es) 2020-10-19
SG11202009179TA (en) 2020-10-29
AU2019249560B2 (en) 2023-10-05
JP7130588B2 (ja) 2022-09-05
US20190330193A1 (en) 2019-10-31
EP3778593A4 (en) 2021-12-22
CO2020012353A2 (es) 2021-01-18
CA3089092A1 (en) 2019-10-10
PH12020551624A1 (en) 2021-07-12
CL2020002550A1 (es) 2021-01-15
IL277686A (en) 2020-11-30
WO2019194207A1 (ja) 2019-10-10
JP2019182852A (ja) 2019-10-24
US20220048896A1 (en) 2022-02-17
AU2019249560A1 (en) 2020-07-23
JP2022166280A (ja) 2022-11-01
EP3778593A1 (en) 2021-02-17
BR112020019939A2 (pt) 2021-01-05
TW201942114A (zh) 2019-11-01
RU2020132318A3 (es) 2022-04-29
RU2020132318A (ru) 2022-04-29
US20240166632A1 (en) 2024-05-23
AR114465A1 (es) 2020-09-09
KR20200139696A (ko) 2020-12-14
ZA202006053B (en) 2022-03-30
US10988462B2 (en) 2021-04-27
JP2024050645A (ja) 2024-04-10
TWI805727B (zh) 2023-06-21

Similar Documents

Publication Publication Date Title
MX2020010433A (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
PH12020551305A1 (en) Pharmaceutical Compounds
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
MX2020014116A (es) Agente profilactico o terapeutico para atrofia muscular espinal.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
TW200740434A (en) A prophylactic and/or therapeutic agent for for sleep disorders
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
GB0112348D0 (en) Compounds
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
MX2021014680A (es) Derivado de benzotriazol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
CR20210284A (es) Pirazoles como modulares de hemoglobina
MX2023000693A (es) Inhibidor de egfr.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4